Skip to main content
    N

    Nurix Therapeutics Inc (NRIX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.73
    -0.75 (-4.84%)

    Market Cap: $1.69B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Nurix Therapeutics Inc (NRIX) P/E Ratio & Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Nurix Therapeutics (NRIX) trades at 6.4x trailing earnings and 2.3x sales. Its P/S of 2.3x is below its 5-year median of 15.1x.

    Current Multiples

    Its enterprise value is 3.1x its EBITDA. Its free cash flow yield is 22.5%.

    MultipleValue
    P/E (trailing)6.4x
    Forward P/EN/A
    Price to sales2.3x
    Price to book1.7x
    EV/EBITDA3.1x
    Price to FCF4.4x
    EV/FCF2.5x
    PEGN/A
    FCF yield22.5%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S2.3x15.1xN/A
    P/B1.7x2.5xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 6 year ends shown, its P/S ranged from 7.3x in 2023 to 48.9x in 2020.

    Year endPriceP/SP/B
    2025$18.9719.3x3.3x
    2024$18.8422.5x2.8x
    2023$10.327.3x2.8x
    2022$10.9813.6x2.0x
    2021$28.9542.1x3.8x
    2020$32.8848.9x4.4x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About NRIX

    Is NRIX stock overvalued?

    GNG's valuation label for NRIX is Undervalued.

    What is NRIX's price to sales ratio?

    Nurix Therapeutics has a price to sales ratio of 2.3x.